At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Durvalumab +1 moredrug
Likely dose
Durvalumab 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 20, 2018·Updated Aug 17, 2025
In Brief
A Phase 2 clinical trial evaluating Durvalumab and Tremelimumab for Intermediate Stage of Hepatocellular Carcinoma and Hepatocellular Carcinoma. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartOct 2019
Primary CompletionAug 2024
TodayJul 2026
First PostedAug 20, 2018
Enrollment StartOct 2, 2019
Primary CompletionAug 20, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.9 years ago
Interventions
Durvalumabdrug
Durvalumab 1500mg IV every 4 weeks for up to a maximum of 13 cycles (about 12 months) or until confirmed disease progression.
Tremelimumabdrug
Tremelimumab 300 mg IV in combination with Durvalumab 1500mg about 2 weeks after their first DEB-TACE.